MX2018009802A - Composiciones novedosas y metodos terapeuticos. - Google Patents

Composiciones novedosas y metodos terapeuticos.

Info

Publication number
MX2018009802A
MX2018009802A MX2018009802A MX2018009802A MX2018009802A MX 2018009802 A MX2018009802 A MX 2018009802A MX 2018009802 A MX2018009802 A MX 2018009802A MX 2018009802 A MX2018009802 A MX 2018009802A MX 2018009802 A MX2018009802 A MX 2018009802A
Authority
MX
Mexico
Prior art keywords
ocular
inflammation
diseases
therapeutic methods
novel compositions
Prior art date
Application number
MX2018009802A
Other languages
English (en)
Inventor
ACHARYA Suchismita
K Panda Santosh
DAS Pragnya
Agarwal Beamon
Original Assignee
Ayuvis Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayuvis Res Inc filed Critical Ayuvis Res Inc
Publication of MX2018009802A publication Critical patent/MX2018009802A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención está dirigida a productos novedosos, variantes, sales farmacéuticamente aceptables y profármacos de los mismos, y el uso médico de esos compuestos para el tratamiento y/o manejo de la sepsis, septicemia, choque séptico, infección ocular, inflamación ocular, angiogénesis ocular, artritis reumatoide (RA), ateroesclerosis, enfermedades intestinales inflamatorias (IBD), asma, enfermedad pulmonar obstructiva crónica, síndromes febriles, caquexia, psoriasis, enfermedades autoinmunes, enfermedades cardiacas, retinoblastoma, cáncer y/o cualquier trastorno asociado con inflamación, inmunomodulación e infección microbiana.
MX2018009802A 2016-03-30 2017-03-30 Composiciones novedosas y metodos terapeuticos. MX2018009802A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662315144P 2016-03-30 2016-03-30
PCT/US2017/024908 WO2017173024A1 (en) 2016-03-30 2017-03-30 Novel compositions and therapeutic methods

Publications (1)

Publication Number Publication Date
MX2018009802A true MX2018009802A (es) 2018-12-06

Family

ID=59958482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009802A MX2018009802A (es) 2016-03-30 2017-03-30 Composiciones novedosas y metodos terapeuticos.

Country Status (10)

Country Link
US (1) US11207343B2 (es)
EP (1) EP3436467A4 (es)
JP (5) JP2019513137A (es)
KR (2) KR102306956B1 (es)
CN (2) CN114712383A (es)
AU (3) AU2017244114B2 (es)
BR (1) BR112018067833B1 (es)
CA (2) CA3015494C (es)
MX (1) MX2018009802A (es)
WO (1) WO2017173024A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2684150C (en) 2007-05-14 2016-10-04 Research Foundation Of State University Of New York Decenoic acid dispersion inducers in the treatment of biofilms
CA3103503A1 (en) * 2018-07-02 2020-01-09 Ayuvis Research, Inc. Novel immunodulating small molecules
EP3820512B1 (en) * 2018-07-02 2024-04-24 Ayuvis Research, Inc. Immunomodulating compositions comprising oligosaccharide derivatives
JP7382281B2 (ja) * 2020-05-25 2023-11-16 株式会社東海理化電機製作所 制御装置および制御方法
JP7382280B2 (ja) 2020-05-25 2023-11-16 株式会社東海理化電機製作所 制御装置および制御方法
WO2022169855A1 (en) * 2021-02-04 2022-08-11 Ayuvis Research, Inc. Chitin analogs for the treatment of kidney diseases
US20230097886A1 (en) * 2021-07-30 2023-03-30 Ayuvis Research, Inc. Compositions and methods for the treatment of bronchopulmonary dysplasia (bpd) and bpd-associated pulmonary hypertension

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152413A (en) 1978-08-18 1979-05-01 Chromalloy American Corporation Oral vaccine for swine dysentery and method of use
CA1261264A (en) 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
US5932640A (en) 1989-01-21 1999-08-03 Clariant Finance (Bvi) Limited Dyeability or mass coloration of synthetic polyamide
JPH041115A (ja) 1990-04-13 1992-01-06 Pola Chem Ind Inc 皮膚外用剤
SG47582A1 (en) 1992-05-07 1998-04-17 American Cyanamid Co Synthetic lipid a glycoconjugate antigens for use in vaccines
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6492350B2 (en) 2000-01-27 2002-12-10 Jdc (Hawaii) Inc. Chitin oligosaccharides and/or chitosan oligosaccharides for preventing or treating common cold or treating pain
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US7098195B2 (en) 2001-11-28 2006-08-29 Health Research, Inc. Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells
AU2002351576A1 (en) 2001-12-13 2003-07-09 Ism Biopolymer Inc. Method of modulating release of saccharides and uses thereof
MXPA04008596A (es) * 2002-03-05 2004-12-06 Ono Pharmaceutical Co Compuestos derivados de 8-azaprostaglandina y farmacos que contienen los compuestos como ingrediente activo.
US7632654B2 (en) * 2002-04-29 2009-12-15 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Means and methods for detecting endoglycosidase activity
EP1440683A1 (de) * 2003-01-23 2004-07-28 Cognis France S.A. Verwendung von Oligoglucosaminen in kosmetischen oder dermatologischen Zubereitungen
JP5035787B2 (ja) 2005-10-04 2012-09-26 焼津水産化学工業株式会社 α−１、４結合型Ｎ−アセチルグルコサミン含有Ｏ−グリカン型糖鎖の分泌促進剤並びにこれを含有するヘリコバクターピロリ菌を原因とする病態の治療予防剤
FR2892419A1 (fr) 2005-10-24 2007-04-27 Univ Claude Bernard Lyon I Eta Heteroligomeres de d-glucasamine et n-acetyl-d-glucosamine, leur procede de preparation et leur utilisation
JP5140246B2 (ja) * 2006-03-15 2013-02-06 公益財団法人野口研究所 Ｎ−アセチルグルコサミンの誘導体を含有するピロリ菌増殖抑制剤
GB0622688D0 (en) 2006-11-14 2006-12-27 Diosamine Dev Corp Novel compounds
CA2724064C (en) * 2008-05-16 2016-05-17 Forskarpatent I Syd Ab Synthesis of galactoside inhibitors
CN101732338A (zh) 2008-11-26 2010-06-16 中国科学院大连化学物理研究所 壳六糖在制备预防血管生成的药物中的应用
US9072760B2 (en) * 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
CN102475714A (zh) 2010-11-29 2012-05-30 中国科学院大连化学物理研究所 壳寡糖单一化合物在免疫增强药物中的应用
WO2014028847A1 (en) 2012-08-17 2014-02-20 The University Of North Carolina At Chapel Hill Water soluble nitric oxide-releasing polyglucosamines and uses thereof
CA2911209A1 (en) 2013-05-14 2014-11-20 Medimmune, Llc Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses thereof

Also Published As

Publication number Publication date
AU2017244114A1 (en) 2018-11-08
CN108884121B (zh) 2022-05-31
JP2020090675A (ja) 2020-06-11
KR102306956B1 (ko) 2021-10-01
CN114712383A (zh) 2022-07-08
AU2021232715A1 (en) 2021-10-14
BR112018067833A2 (pt) 2019-03-19
EP3436467A1 (en) 2019-02-06
KR20210122865A (ko) 2021-10-12
JP2023179505A (ja) 2023-12-19
WO2017173024A1 (en) 2017-10-05
JP2020193215A (ja) 2020-12-03
US11207343B2 (en) 2021-12-28
EP3436467A4 (en) 2020-03-18
CA3128743A1 (en) 2017-10-05
JP2019513137A (ja) 2019-05-23
AU2023222844A1 (en) 2023-09-14
CA3015494C (en) 2021-10-26
CN108884121A (zh) 2018-11-23
US20170281667A1 (en) 2017-10-05
AU2017244114B2 (en) 2021-07-22
CA3015494A1 (en) 2017-10-05
KR20180125583A (ko) 2018-11-23
JP7357364B2 (ja) 2023-10-06
BR112018067833B1 (pt) 2024-03-05
JP2024041834A (ja) 2024-03-27
KR102532825B1 (ko) 2023-05-17

Similar Documents

Publication Publication Date Title
MX2018009802A (es) Composiciones novedosas y metodos terapeuticos.
MX2016013049A (es) Inhibidores de autotaxina espirociclicos sustituidos.
PH12016502045A1 (en) Aryl and heteroaryl ether compounds as ror gamma modulators
CY1119352T1 (el) Ενωσεις και φαρμακευτικες συνθεσεις αυτων για την αγωγη φλεγμονωδων διαταραχων
CY1117204T1 (el) ΕΝΩΣΕΙΣ ΤΡΙΑΖΟΛΟΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ mPGES-1
PH12018500251A1 (en) Novel compounds as ror gamma modulators
EP3606535A4 (en) TREATMENT OF INFLAMMATORY INTESTINAL DISEASES WITH 2'-FUCOSYL LACTOSE COMPOUNDS
WO2015143652A8 (en) TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
EP3866781A4 (en) NEW COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISEASES
MX2018003008A (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos.
EA201700042A1 (ru) Соединения имидазопиридазина
MX2016013329A (es) 2-amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8h )-il-1,3-tiazol-4-ilamidas.
TN2016000511A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
GB201907616D0 (en) Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
GB201610056D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
ZA202100272B (en) Highly purified fucans for the treatment of fibrous adhesions
GB201610055D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
PH12017500383B1 (en) Pyrazolothiazole compound and medicine comprising same
EP3440045A4 (en) PREVENTION, TREATMENT AND REVERSE OF A DISEASE USING THERAPEUTICALLY EFFECTIVE QUANTITIES OF DICARBOXYLIC ACID COMPOUNDS
PH12016502432A1 (en) 1h-1,8-naphthyridin-2-ones as anti proliferative compounds
MX2018010334A (es) Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak).
PH12018500411A1 (en) Novel carbocyclic compounds as ror gamma modulators
EP3937947A4 (en) TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP3880668C0 (en) PYRIDINE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY HEPATITIS